REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) Designated Organic Active Ingredient Containing (doai)Designated Organic Active Ingredient Containing (doai) patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.02/22/07 - 20070042935 - Quinazolinone-derivatives and their use for preparation of pharmaceutical compositions having parp enzyme inhibitory effect The subject of the present invention are quinazoline derivatives and their pharmaceutically acceptable salts of general formula (I), that inhibit a DNA-repairing enzyme, poly(ADP-ribose) polymerase (PARP), enabling them to be used for the preparation of pharmaceutical compositions for preventing or treating illnesses where PARP-inhibition yields a beneficial effect. In general ... 12/14/06 - 20060281666 - Substitute thiophenes and uses therof This invention relates to novel compounds having the structural formula (I) and to their pharmaceutical salts, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cancer. ... 10/19/06 - 20060234904 - Method for preparing polymorphism of irinotecan hydrochloride A method for preparing a novel crystalline polymorphic irinotecan hydrochloride which is excellent in the solubility in water and reduced in the content of impurities is provided. A method for preparing c-type crystals of irinotecan hydrochloride having diffraction peaks (2θ) at 9.15°, 10.00°, 11.80°, 12.20°, 13.00° and 13.40° in the ... 09/21/06 - 20060211599 - Reversibly heat-gelable aqueous composition The present invention relates to a reversibly heat-gelable aqueous composition comprising a reversibly heat-gelable aqueous composition according to conventional technique, to which a thixotropic property-increasing substance is added. The thixotropic property-increasing substance is preferably at least one member selected from the group consisting of sugar alcohol, lactose, carmellose or pharmaceutically ... 04/20/06 - 20060084590 - Methods of and compounds for modulating the activity of bacterial fabg Prokaryotic FAB G polypeptides and DNA (RNA) encoding such FAB G and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such FAB G for the treatment of infection, such as bacterial infections. Antagonists against such FAB G and their use as ... 03/23/06 - 20060063697 - Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses The present invention relates to immunotherapy methods for treating hyperproliferative disease or pathogen-induced diseases in humans. More specifically, the invention is directed, in one embodiment, to methods for treating a subject with a hyperproliferative disease in which the expression of a self gene is upregulated in hyperproliferative cells. In another ... 03/09/06 - 20060052279 - Labeling proteins with dyes that are insoluble or only sparingly soluble in water The proteins in a biological sample that is sought to be analyzed for its protein composition by an electrophoretic or chromatographic procedure are coupled to a dye in an unusually efficient manner by combining the sample with a solid dry composition containing the dye, a buffering agent, and in preferred ... 03/09/06 - 20060052278 - Diagnosis and treatment of human dormancy-related sequellae New methods for diagnosis and treatment of human dormancy syndrome-related sequellae are provided. Human dormancy syndrome (HDS) is characterized by elevated serum ratio of rT3/fT3 compared to a population of normal subjects. HDS includes fibromyalgia, chronic fatigue, cancer, autoimmune disease, obesity and related dormancy conditions. Dormancy and HDS-related sequellae are ... 02/16/06 - 20060035810 - Regulation of ins(3456)p4 signalling by a reversible kinase phosphatase and methods and compositions related thereto Provided is a method of increasing 3,4,5,6-tetrakisphosphate by increasing the activity of inositol 1,3,4,5,6 pentakisphosphate 1-phosphatase, and a method of decreasing 3,4,5,6-tetrakisphosphate by decreasing the activity of inositol 1,3,4,5,6 pentakisphosphate 1-phosphatase. A method of reducing salt, fluid or mucous secretion in a subject, comprising increasing the activity of inositol 1,3,4,5,6 ... 02/16/06 - 20060035809 - Apoptosis-mimicking natural vesicles and use thereof in medical treatment Natural biological vesicles with membranes which have lost phospholipid symmetry, especially those presenting phosphatidyl serine on outer membrane surfaces, such as red cell ghosts, are administered to mammalian patients, in immune system modifying amounts, for treatment or prophylaxis of inflammatory cytokine-related disorders, including autoimmune disorders, neurodegenerative disorders and endothelial dysfunction ... 11/24/05 - 20050261165 - Methods of reducing microbial resistance to drugs The instant methods and compositions represent an advance in controlling drug resistance in microbes. AcrAB-like efflux pumps have been found to control resistance to drugs, even in highly resistant microbes. Accordingly, methods of treating infection, methods of screening for inhibitors of AcrAB-like efflux pumps, and methods of enhancing antimicrobial activity ... 11/24/05 - 20050261164 - Remedy for urinary frequency and urinary incontinence A composition for treating frequent urination and/or urinary incontinence comprising a compound having an activity to inhibit Na+/H+ exchange transporter or its pharmaceutically acceptable salt as an active ingredient. ... 11/24/05 - 20050261163 - Pharmaceutical products, preparation and uses thereof A pharmaceutical product comprising at least one therapeutic agent, whereby a unit dose of said therapeutic agent as provided by said pharmaceutical product can be administered to a patient during the passage of said therapeutic agent through the gastrointestinal tract of the patient, wherein said therapeutic agent is characterised as ... 11/24/05 - 20050261162 - Pharmaceutical composition for preventing and treating cancer and treating an inflammation The present invention relates to a pharmaceutical composition preventing cancer and treating cancer and inflammation, which is characterized in that including xanthorrhizol as an active principle. Xanthorrhizol not only inhibits mutagenesis and tumor formation, and enhances the activity of detoxification enzyme of carcinogen, induces apoptosis of cancer cell, and suppresses ... 11/24/05 - 20050261161 - Stable crystals of pyrrole compound The present invention is constituted with crystal of 2-amino-3-cyano-4-methyl-5-(2-fluorophenyl)pyrrole, which show diffraction peaks at diffraction angles (2θ±0.2 degree) of 10.3 degree, 14.3 degree, 15.5 degree, 15.9 degree, 25.1 degree and 25.7 degree in a powder X-ray diffraction spectrum, and also show absorption peaks at wavenumbers (cm−1, ±0.2%) of 3373, 3322, ... 11/10/05 - 20050250672 - Preparation for the prophylaxis of restenosis The invention relates to a preparation for restenosis prevention. The preparations for restenosis prevention known as yet do not reach sufficient active agent concentrations in the affected sections of the vascular walls as higher doses cause undesirable side effects. The present invention is a preparation to which at least one ... 11/10/05 - 20050250671 - Activators of peroxisome proliferator-activated receptor Activators of peroxisome proliferator-activated receptors comprising a polyprenyl compound, preferably (2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid, as an active ingredient, and medicaments for preventive and/or therapeutic treatment of hyperlipidemia, non-insulin dependent diabetes mellitus or the like comprising a polyprenyl compound as an active ingredient. ... 09/01/05 - 20050192208 - Ion channel modulating compounds and uses thereof Ion channel modulating compounds are disclosed. The compounds of the present invention may be incorporated in compositions and kits. The present invention also discloses a variety of in vitro and in vivo uses for the compounds and compositions, including the treatment of arrhythmia and the production of analgesia ... 08/11/05 - 20050176619 - Antitumoral formulations of thioxanthenone The invention relates to a formulation of N-[[1-[[2-(diethylamino)ethyl]amino]-7-methoxy-9-oxothioxanthen-4-yl]-methyl]formamide, or a pharmaceutically acceptable acid-addition salt thereof, and to the method of use thereof in the treatment of tumors and cancers. ... 08/04/05 - 20050170999 - Excitatory amino acid receptor antagonists The present invention provides novel compounds of Formula I or Formula II, or the pharmaceutically acceptable salts or prodrugs thereof, pharmaceutical compositions comprising an effective amount of a compound of Formula I or Formula II in combination with a suitable carrier, diluent, or excipient, and methods for treating neurological disorders ... 07/14/05 - 20050153870 - Medicinal composition for diagnosis, prevention, or therapy of multiple risk factor syndrome the hydrogen atom of at least one of the hydroxyl groups is substituted by a group selected from the group consisting of (C1-C15) alkyl, (C2-C15) alkenyl, (C1-C15) alkylnyl, aryl, (C1-C15) alkylaryl; —(CnH2n)R (where n is an integer of 1 to 15 and R represents COOR′ which substitutes for any one ... ### FreshPatents.com Support |